Cognixion has signed a distribution agreement with Blackrock Neurotech to bring its non-invasive Axon-R brain-computer interface (BCI) device to more research institutions. The wearable neural interface uses EEG and AR, paired with generative AI, to help non-verbal individuals communicate rapidly and naturally—surpassing traditional text-to-speech tools.
Blackrock Neurotech, known for its implantable BCI systems, will distribute Axon-R non-exclusively, expanding access to cutting-edge, research-grade tools. While Blackrock remains focused on clinical implants like its NeuroPort and MoveAgain systems, this collaboration taps into a wider innovation pipeline.
The U.S. BCI market is projected to reach $400 billion, and both companies aim to play leading roles in shaping its future.
Follow MEDWIRE.AI for neurotech and BCI updates.
